ATXS
Price
$12.45
Change
-$0.04 (-0.32%)
Updated
Nov 19, 04:59 PM (EDT)
Capitalization
710.14M
105 days until earnings call
Intraday BUY SELL Signals
ENSC
Price
$1.80
Change
-$0.13 (-6.74%)
Updated
Nov 19, 04:59 PM (EDT)
Capitalization
5.36M
Intraday BUY SELL Signals
Interact to see
Advertisement

ATXS vs ENSC

Header iconATXS vs ENSC Comparison
Open Charts ATXS vs ENSCBanner chart's image
Astria Therapeutics
Price$12.45
Change-$0.04 (-0.32%)
Volume$6.12K
Capitalization710.14M
Ensysce Biosciences
Price$1.80
Change-$0.13 (-6.74%)
Volume$300
Capitalization5.36M
ATXS vs ENSC Comparison Chart in %
ATXS
Daily Signal:
Gain/Loss:
ENSC
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
ATXS vs. ENSC commentary
Nov 20, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ATXS is a Hold and ENSC is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Nov 20, 2025
Stock price -- (ATXS: $12.49 vs. ENSC: $1.93)
Brand notoriety: ATXS and ENSC are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ATXS: 31% vs. ENSC: 74%
Market capitalization -- ATXS: $710.14M vs. ENSC: $5.36M
ATXS [@Biotechnology] is valued at $710.14M. ENSC’s [@Biotechnology] market capitalization is $5.36M. The market cap for tickers in the [@Biotechnology] industry ranges from $106.82B to $0. The average market capitalization across the [@Biotechnology] industry is $2.15B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ATXS’s FA Score shows that 0 FA rating(s) are green whileENSC’s FA Score has 1 green FA rating(s).

  • ATXS’s FA Score: 0 green, 5 red.
  • ENSC’s FA Score: 1 green, 4 red.
According to our system of comparison, both ATXS and ENSC are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ATXS’s TA Score shows that 3 TA indicator(s) are bullish while ENSC’s TA Score has 4 bullish TA indicator(s).

  • ATXS’s TA Score: 3 bullish, 5 bearish.
  • ENSC’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, both ATXS and ENSC are a bad buy in the short-term.

Price Growth

ATXS (@Biotechnology) experienced а -0.12% price change this week, while ENSC (@Biotechnology) price change was -5.39% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -2.17%. For the same industry, the average monthly price growth was -5.68%, and the average quarterly price growth was +64.91%.

Reported Earning Dates

ATXS is expected to report earnings on Mar 05, 2026.

Industries' Descriptions

@Biotechnology (-2.17% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ATXS($710M) has a higher market cap than ENSC($5.36M). ATXS YTD gains are higher at: 39.150 vs. ENSC (-77.826). ENSC has higher annual earnings (EBITDA): -6.56M vs. ATXS (-131.42M). ATXS has more cash in the bank: 259M vs. ENSC (2.21M). ENSC has less debt than ATXS: ENSC (425K) vs ATXS (4.77M). ATXS (0) and ENSC (0) have equivalent revenues.
ATXSENSCATXS / ENSC
Capitalization710M5.36M13,251%
EBITDA-131.42M-6.56M2,003%
Gain YTD39.150-77.826-50%
P/E RatioN/A0.02-
Revenue00-
Total Cash259M2.21M11,709%
Total Debt4.77M425K1,121%
FUNDAMENTALS RATINGS
ATXS vs ENSC: Fundamental Ratings
ATXS
ENSC
OUTLOOK RATING
1..100
8758
VALUATION
overvalued / fair valued / undervalued
1..100
76
Overvalued
19
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
96100
PRICE GROWTH RATING
1..100
3585
P/E GROWTH RATING
1..100
10068
SEASONALITY SCORE
1..100
9050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ENSC's Valuation (19) in the null industry is somewhat better than the same rating for ATXS (76) in the Biotechnology industry. This means that ENSC’s stock grew somewhat faster than ATXS’s over the last 12 months.

ENSC's Profit vs Risk Rating (100) in the null industry is in the same range as ATXS (100) in the Biotechnology industry. This means that ENSC’s stock grew similarly to ATXS’s over the last 12 months.

ATXS's SMR Rating (96) in the Biotechnology industry is in the same range as ENSC (100) in the null industry. This means that ATXS’s stock grew similarly to ENSC’s over the last 12 months.

ATXS's Price Growth Rating (35) in the Biotechnology industry is somewhat better than the same rating for ENSC (85) in the null industry. This means that ATXS’s stock grew somewhat faster than ENSC’s over the last 12 months.

ENSC's P/E Growth Rating (68) in the null industry is in the same range as ATXS (100) in the Biotechnology industry. This means that ENSC’s stock grew similarly to ATXS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ATXSENSC
RSI
ODDS (%)
Bearish Trend 2 days ago
77%
Bullish Trend 2 days ago
84%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
85%
Bullish Trend 2 days ago
82%
Momentum
ODDS (%)
Bullish Trend 2 days ago
79%
Bearish Trend 2 days ago
90%
MACD
ODDS (%)
Bearish Trend 2 days ago
83%
Bearish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
90%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
87%
Bearish Trend 2 days ago
90%
Advances
ODDS (%)
Bullish Trend 10 days ago
81%
Bullish Trend 6 days ago
80%
Declines
ODDS (%)
Bearish Trend 16 days ago
90%
Bearish Trend 2 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 7 days ago
83%
Bullish Trend 2 days ago
86%
Aroon
ODDS (%)
Bullish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
ATXS
Daily Signal:
Gain/Loss:
ENSC
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
GINNX65.950.30
+0.46%
Guinness Atkinson™ Global Inntrs Instl
CMGSX35.74N/A
N/A
BlackRock Mid-Cap Growth Equity Svc
JMIGX32.47N/A
N/A
Jacob Discovery Fd Instl
POICX11.24N/A
N/A
Virtus Tactical Allocation C
CSVRX43.96N/A
N/A
Columbia Small Cap Value Discv R

ATXS and

Correlation & Price change

A.I.dvisor indicates that over the last year, ATXS has been loosely correlated with XENE. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if ATXS jumps, then XENE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ATXS
1D Price
Change %
ATXS100%
-0.40%
XENE - ATXS
49%
Loosely correlated
+0.15%
SYRE - ATXS
49%
Loosely correlated
+0.83%
RGNX - ATXS
48%
Loosely correlated
-2.84%
ORKA - ATXS
46%
Loosely correlated
+2.73%
CRNX - ATXS
45%
Loosely correlated
-0.23%
More

ENSC and

Correlation & Price change

A.I.dvisor indicates that over the last year, ENSC has been loosely correlated with MLLCF. These tickers have moved in lockstep 37% of the time. This A.I.-generated data suggests there is some statistical probability that if ENSC jumps, then MLLCF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ENSC
1D Price
Change %
ENSC100%
-6.48%
MLLCF - ENSC
37%
Loosely correlated
N/A
HNSBF - ENSC
33%
Loosely correlated
N/A
SYRE - ENSC
31%
Poorly correlated
+0.83%
ATXS - ENSC
31%
Poorly correlated
-0.40%
NEUP - ENSC
31%
Poorly correlated
-7.17%
More